In fact, one of the first human trials of [225Ac]Ac-PSMA-617 demonstrated an impressive response where the PSA value of a patient with metastatic prostate cancer was reduced from 2,923 ng/mL to less than 0.1 ng/mL after 4 cycles of therapy with [225Ac]Ac-PSMA-617 (Kratochwil et al. 2016). Here, FOLH1 is linked to metastatic prostate carcinoma.